Introduction
============

Chronic kidney disease (CKD) is defined as either structural and/or functional abnormality of the kidney or reduced glomerular filtration rate (GFR) to a level less than 60 ml/min/1.73 m^2^.[@b1-vhrm-5-315],[@b2-vhrm-5-315] CKD has recently been recognized as a challenging public health issue not only because numbers of patients with end-stage renal disease (ESRD) are steadily increasing in developed countries including Japan, but also because recent epidemiological studies showed that CKD is a significant risk factor for cardiovascular disease.[@b3-vhrm-5-315]--[@b5-vhrm-5-315] For example, the number of ESRD patients in Japan is currently greater than 250,000, and this has become an economic burden for the health care system.[@b6-vhrm-5-315] On the other hand, it was shown in a Japanese community by a prospective study that ischemic heart disease and cerebral infarction are more frequent in the male and female residents with CKD, respectively, than in those without it.[@b5-vhrm-5-315] In order to prevent or reduce development of CKD at a community level, it is essential to identify or specify the cause(s) of CKD. Because GFR is reduced by aging, CKD is more frequent in elderly people than in younger ones. Besides aging, possible factors involved in the development of CKD are hypertension, impaired glucose tolerance or diabetes mellitus, dyslipidemia and obesity,[@b7-vhrm-5-315]--[@b14-vhrm-5-315] but the detailed mechanism(s) remains to be clarified. In the present study, we carried out a community-based, cross-sectional study of the local residents of the Kiyotake area in an attempt to identify the factor(s) associated with CKD.

Materials and methods
=====================

Study subjects and protocol
---------------------------

In this study, we examined local residents in the Kiyotake area, Miyazaki, Japan, who had an annual health check-up from September to October of 2006 responding to the recommendation made by the municipal government for those of 40 years or older. Upon visiting the community center of Kiyotake town, medical history of the subjects was taken by nurses and confirmed by physicians, and blood pressure was measured with an oscillometric automatic device (BP-103iII; Colin Japan Ltd, Tokyo, Japan) in a sitting position by experienced nurses. Urine was collected and blood was drawn from an antecubital vein after overnight fast. Serum lipid and glucose levels were measured by the automatic analyzer (Olympus AU2700; Olympus, Tokyo, Japan) with serum creatinine levels determined by the enzymatic method. GFRs were calculated with the formula of 0.741 × 175 × Age^−0.203^ × serum creatinine^−1.154^ (further multiplied by 0.742 for females), the Modification of Diet in Renal Disease (MDRD) Study equation further modified for Japanese people by the Japanese Society of Nephrology.[@b15-vhrm-5-315],[@b16-vhrm-5-315] Residents were judged to have CKD when estimated GFR (eGFR) \<60 ml/min/1.73 m^2^ or spot urine protein determined by dipstick measurement ≥ + 1 (30 mg/dl). Obesity was defined with body mass index (BMI) of 25 kg/m^2^ or larger, according to the criteria of the Japan Society for the Study of Obesity.[@b17-vhrm-5-315]

In this health check-up program, 2085 residents (761 males, 63.1 ± 10.7 years; 1324 females, 59.8 ± 10.9 years; mean ± SD) visited during the time period mentioned above. From those subjects, not to analyze CKD closely related with diabetic nephropathy, we excluded residents with fasting blood glucose levels of 126 mg/dl or higher (n = 80), or those who were taking glucose--lowering agents or had been diagnosed as having diabetes mellitus by any physician (n = 55). In addition, two male residents who had renal failure with eGFR less than 15 ml/min/1.73 m^2^ were excluded from the analysis. As a result, we finally analyzed the data from 1978 local residents (697 males, 63.0 ± 10.8 years; 1281 females, 59.6 ± 10.9 years). This study was approved by the Review Committee of Cooperative and Commissioned Research and the Ethics Committee of University of Miyazaki Faculty of Medicine.

Statistical analysis
--------------------

All the data were analyzed with SPSS software version 17.0 (SPSS Inc., Chicago, IL). Comparisons of two groups were assessed by unpaired *t*-test or Chi-squared test, and the relationship between BMI and eGFR was evaluated by linear regression analysis. The data were further examined by univariate and then multivariate logistic methods to extract significant, independent factors for CKD. All the data were expressed as means ± SD and a P value less than 0.05 was considered to be significant.

Results
=======

[Table 1](#t1-vhrm-5-315){ref-type="table"} shows the basal profiles of the male and female residents examined in this study. As shown, 22.8% of male and 15.7% of female residents were found to have CKD, diagnosis of which was made by estimated GFR \<60 ml/min/1.73 m^2^ in 330 residents, by dipstick proteinuria ≥ + 1 in 16 or by both in 14. Expectedly, the mean ages in the male and female residents with CKD were higher (P \< 0.01) than in those without CKD. When compared with the residents without CKD, BMI of both genders was slightly, but significantly higher in those with CKD, resulting in significantly increased prevalence of obesity. When analyzed by linear regression analysis, BMI was found to be significantly correlated with eGFR in both genders ([Figure 1](#f1-vhrm-5-315){ref-type="fig"}). Current smoker ratio in the male CKD residents was lower than in the controls (P \< 0.05), while no difference was noted in the female residents. Both the systolic and diastolic blood pressure levels in the CKD subjects were higher than in the controls in male (P \< 0.01), but this was not the case for female. Meanwhile, ratios of subjects who were taking antihypertensive medicines in the CKD residents were significantly higher than in those without CKD in both genders. The fasting blood glucose (FBG) levels of the males (P \< 0.05) and the triglyceride level of the females (P \< 0.01) with CKD were found to be higher, compared with those without it, while there were no significant differences in ratio of the residents taking antidyslipidemic medicines. The number of residents who had a family history of cardiovascular diseases (CVD) was slightly higher in the residents with CKD in both genders, but the differences were not statistically significant.

The results of univariate and multivariate logistic analyses are shown in [Table 2](#t2-vhrm-5-315){ref-type="table"} for males and in [Table 3](#t3-vhrm-5-315){ref-type="table"} for females. In the univariate analyses, age, BMI and antihypertensive medication were found to be significant for CKD in both genders, and in addition, judged to be significant were smoking, blood pressure and FBG for males and triglyceride for females. Because differences were noted in smoking, blood pressure, antihypertensive medication, triglyceride, and FBG between those with and without CKD, we next analyzed the data by means of a multivariate logistic analysis using CKD as a dependent variable and the parameters listed in [Tables 2](#t2-vhrm-5-315){ref-type="table"} and [3](#t3-vhrm-5-315){ref-type="table"} as independent covariates. As shown, smoking, blood pressure, antihypertensive medication, and FBG became insignificant, but BMI was found to be independently significant for CKD as well as age in both genders, and in females, triglyceride was a significant factor.

Discussion
==========

Chronic kidney disease (CKD) has recently been recognized not only as a risk factor of ESRD, but also of CVD which is a leading cause of death in developed countries.[@b1-vhrm-5-315],[@b2-vhrm-5-315],[@b6-vhrm-5-315] An interventional approach is necessary to prevent development of CKD at a community level, while the detailed mechanisms by which CKD develops remained to be specified. In the present study, we conducted this cross-sectional, observational study in the Kiyotake area, a Japanese community, and found that an increase in BMI is a significant factor independently associated with CKD.

Age is an important factor closely related with CKD because GFR is reduced by aging, while a number of factors have been shown to be associated with CKD besides aging. These are hypertension, impaired glucose tolerance or diabetes mellitus, dyslipidemia, obesity, and smoking.[@b7-vhrm-5-315]--[@b14-vhrm-5-315] In the present study, to avoid including CKD secondary to diabetic nephropathy, we excluded subjects with diabetes mellitus or with a fasting blood glucose level of 126 mg/dl or higher. As shown in the basal profiles of the residents with CKD, the blood pressure and FBG level of males and the triglyceride level of females were significantly elevated, and the ratios of subjects taking antihypertensive medicine were higher in both genders, compared with those without CKD. Indeed, these parameters were significant for CKD in the univariate logistic analysis. But in the multivariate analysis, they were judged to be insignificant except for triglyceride in females, while BMI, as well as age, was extracted as an independently significant factor for CKD.

Hypertension has been clearly shown to be an important risk factor for future reduction in GFR and development of ESRD,[@b7-vhrm-5-315],[@b8-vhrm-5-315] but we found no significant association between CKD and blood pressure in the present study despite the fact that both the systolic and diastolic blood pressure levels were higher in the males with CKD than without CKD. The lack of association can be attributed to the close relationship between age and blood pressure levels, because blood pressure was judged to be significant for CKD by univariate analysis, but became insignificant when adjusted with the other parameters including age ([Table 2](#t2-vhrm-5-315){ref-type="table"}). Obesity has also been recognized as a factor related with CKD, but there has been no clear answer to an important question: what is the underlying mechanism of CKD developing in association with increased BMI. Assumed to be involved are the activated renin--angiotensin system, increased sympathetic nerve activity, insulin-resistance or hyperinsulinemia and dyslipidemia.[@b7-vhrm-5-315]--[@b14-vhrm-5-315],[@b18-vhrm-5-315] It was reported that impaired glucose tolerance (IGT) is associated with development of CKD.[@b11-vhrm-5-315],[@b19-vhrm-5-315] The residents with diabetes mellitus or with a fasting blood glucose level of 126 mg/dl or higher were excluded, while neither glucose tolerance test nor measurement of insulin levels was done in the present study. Therefore, either IGT or hyperinsulinemia associated with increased BMI may be a possible explanation for the correlation between CKD and BMI. The independent association between CKD and triglyceride level in the female residents of this study appears to accord with this notion.

The present findings are also comparable with the report by Tanaka and colleagues, who showed that metabolic syndrome is an independent, significant determinant of CKD in a hospital--based screening program in Japan.[@b20-vhrm-5-315] In the present study, the differences in BMI or the percentages of obese subjects are relatively small between those with and without CKD, though BMI was extracted as a significant factor independent of blood pressure, serum HDL, triglyceride and FBG levels, which are important factors in criteria of metabolic syndrome. It has been thought that Asians including Japanese are susceptible to increased body weight in terms of development of metabolic disorders including diabetes mellitus: for example, there is a notable difference between the definition of obesity for Caucasians and that for Japanese.[@b17-vhrm-5-315],[@b21-vhrm-5-315] It is possible that Japanese are also susceptible to increased body weight in terms of development of CKD, but this hypothesis, as well as the detailed mechanisms of development of CKD associated with increased BMI, should be clarified by future studies. Recently it was reported that significant association between CKD and BMI was found in men but not in women by two epidemiological studies done by Ishizaka and colleagues in Japan and by Shankar and colleagues in Singapore.[@b22-vhrm-5-315],[@b23-vhrm-5-315] The significant association found in the females of the present study is inconsistent with those reports. We have no clear explanation for this discrepancy, while may be able to raise a possibility of difference in age of study subjects. The mean age of the female subjects examined by Ishizaka and colleagues was younger than that of the present study. Age of female subjects may be an important factor influencing results of this type of epidemiological study, because estrogens, blood levels of which decline after menopause, have been shown to exert a protective action on kidneys.[@b24-vhrm-5-315]

Lastly, we should mention the limitations of the present study. First, the subjects examined in the present study were local residents, who had the health check-up in response to the recommendation of the municipal government. Therefore, it should be noted that the subjects examined are not necessarily a group of people representative of those residing in the Kiyotake area in terms of basal profiles of cardiovascular risk factors, such as age and CKD. Next, this is a simply observational study examining the cross-sectional relationship between BMI and CKD, and interventional, follow-up studies are required to see the effect of body weight reduction on development of CKD.

We are grateful to Mr Kazutoshi Abumi, the Mayor of Kiyotake, and the staff of Kiyotake Town Department of Welfare and Health for their assistance. The authors report no conflicts of interest in this work.

![Linear regression analyses of relationship between eGFR and BMI in the male **a**) and female **b**) residents. Regression lines and 95% confidence limits are shown in each graph.\
**Abbreviations:** BMI, body mass index; eGFR, estimated glomerular filtration rate.](vhrm-5-315f1){#f1-vhrm-5-315}

###### 

Basal profiles of male and female residents with or without CKD

  **CKD**                         **Male**      **Female**                                                           
  ------------------------------- ------------- ------------------------------------------------------ ------------- -------------------------------------------------------
  n                               538           159                                                    1080          201
  Age (year)                      61.8 ± 10.8   66.9 ± 9.8[b](#tfn4-vhrm-5-315){ref-type="table-fn"}   58.7 ± 10.4   64.7 ± 12.1[b](#tfn4-vhrm-5-315){ref-type="table-fn"}
  BMI (Kg/m^2^)                   20.0 ± 2.8    23.9 ± 2.8[b](#tfn4-vhrm-5-315){ref-type="table-fn"}   21.9 ± 3.1    22.5 ± 3.2[a](#tfn3-vhrm-5-315){ref-type="table-fn"}
  Obesity (%)                     23.2          32.1[a](#tfn3-vhrm-5-315){ref-type="table-fn"}         13.5          18.9[a](#tfn3-vhrm-5-315){ref-type="table-fn"}
  Smoking (%)                     28.3          18.9[a](#tfn3-vhrm-5-315){ref-type="table-fn"}         3.1           2.0
  SBP (mmHg)                      128 ± 18      135 ± 18[b](#tfn4-vhrm-5-315){ref-type="table-fn"}     122 ± 18      125 ± 17
  DBP (mmHg)                      79 ± 10       82 ± 10[b](#tfn4-vhrm-5-315){ref-type="table-fn"}      73 ± 10       73 ± 9
  Antihypertensive medicine (%)   17.3          27.0[b](#tfn4-vhrm-5-315){ref-type="table-fn"}         12.1          21.4[b](#tfn4-vhrm-5-315){ref-type="table-fn"}
  Total cholesterol (mg/dl)       199 ± 32      201 ± 31                                               214 ± 35      215 ± 36
  HDL-cholesterol (mg/dl)         56 ± 13       54 ± 12                                                64 ± 14       62 ± 16
  Triglyceride (mg/dl)            112 ± 80      123 ± 83                                               91 ± 45       101 ± 56[a](#tfn3-vhrm-5-315){ref-type="table-fn"}
  Antidyslipidemic medicine (%)   2.2           2.5                                                    7.5           7.5
  FBG (mg/dl)                     94.5 ± 9.1    96.5 ± 9.8[a](#tfn3-vhrm-5-315){ref-type="table-fn"}   91.4 ± 8.5    91.7 ± 7.9
  EGFR (ml/min/1.73m^2^)          72 ± 10       54 ± 8[b](#tfn4-vhrm-5-315){ref-type="table-fn"}       75 ± 12       53 ± 8[b](#tfn4-vhrm-5-315){ref-type="table-fn"}
  Family history of CVD (%)       20.3          27.7                                                   23.4          28.4

**Abbreviations:** BMI, body mass index; SBP and DBP, systolic and diastolic blood pressure; HDL, high-density lipoprotein; FBG, fasting blood glucose; eGFR, estimated GFR; CVD, cardiovascular disease.

Definition of obesity, BMI\> = 25.0 Kg/m^2^; Mean+/−SD;

^a^P \< 0.05,

^b^P \< 0.01, vs male or female residents without CKD.

###### 

Identification of factor(s) associated with CKD by univariate and multivariate logistic analyses in male subjects

  **Male**                                                               **Univariate**                                     **Multivariate**                                                     
  ---------------------------------------------------------------------- -------------------------------------------------- ------------------ ------------------------------------------------- --------------
  Age (year)                                                             1.048[b](#tfn7-vhrm-5-315){ref-type="table-fn"}    1.029--1.067       1.062[b](#tfn7-vhrm-5-315){ref-type="table-fn"}   1.038--1.088
  BMI (Kg/m^2^)                                                          1.125[b](#tfn7-vhrm-5-315){ref-type="table-fn"}    1.055--1.200       1.139[b](#tfn7-vhrm-5-315){ref-type="table-fn"}   1.055--1.230
  Smoking[c](#tfn8-vhrm-5-315){ref-type="table-fn"}                      0.591[a](#tfn6-vhrm-5-315){ref-type="table-fn"}    0.381--0.916       0.801                                             0.500--1.282
  SBP (mmHg)                                                             1.020[b](#tfn7-vhrm-5-315){ref-type="table-fn"}    1.010--1.030       0.996                                             0.979--1.013
  DBP (mmHg)                                                             1.027[b](#tfn7-vhrm-5-315){ref-type="table-fn"}    1.009--1.046       1.021                                             0.992--1.051
  Antihypertensive medicine[c](#tfn9-vhrm-5-315){ref-type="table-fn"}    1.774[b](#tfn7-vhrm-5-315){ref-type="table-fn"}    1.171--2.687       1.108                                             0.695--1.766
  Total cholesterol (mg/dl)                                              1.002                                              0.997--1.008       1.003                                             0.997--1.010
  HDL-cholesterol (mg/dl)                                                0.988                                              0.974--1.001       0.996                                             0.979--1.013
  Triglyceride (mg/dl)                                                   1.001                                              0.999--1.004       1.002                                             0.999--1.004
  Antidyslipidemic medicine[c](#tfn10-vhrm-5-315){ref-type="table-fn"}   1.131                                              0.360--3.557       0.698                                             0.209--2.325
  FBG (mg/dl)                                                            1.022[a](#tfn6-vhrm-5-315){ref-type="table-fn"}a   1.003--1.041       1.001                                             0.981--1.022

**Abbreviations:** BMI, body mass index; SBP and DBP, systolic and diastolic blood pressure; HDL, high-density lipoprotein; FBG, fasting blood glucose.

**Notes:** ^a^P \< 0.05,

^b^P \< 0.01,

^c^Smoking,

^c^Antihypertensive medicine,

^c^Antidyslipidemic medicine, (no = 1 and yes = 2).

###### 

Identification of factor(s) associated with CKD by univariate and multivariate logistic analyses in female subjects

  **Female**                                                             **Univariate**                                     **Multivariate**                                                      
  ---------------------------------------------------------------------- -------------------------------------------------- ------------------ -------------------------------------------------- --------------
  Age (year)                                                             1.054[b](#tfn13-vhrm-5-315){ref-type="table-fn"}   1.038--1.069       1.062[b](#tfn13-vhrm-5-315){ref-type="table-fn"}   1.043--1.081
  BMI (Kg/m^2^)                                                          1.056[a](#tfn12-vhrm-5-315){ref-type="table-fn"}   1.008--1.107       1.071[a](#tfn12-vhrm-5-315){ref-type="table-fn"}   1.013--1.132
  Smoking[c](#tfn14-vhrm-5-315){ref-type="table-fn"}                     0.625                                              0.219--1.780       0.795                                              0.272--2.321
  SBP (mmHg)                                                             1.007                                              0.999--1.016       0.991                                              0.976--1.006
  DBP (mmHg)                                                             1.001                                              0.986--1.016       0.995                                              0.972--1.020
  Antihypertensive medicine[c](#tfn15-vhrm-5-315){ref-type="table-fn"}   1.972[b](#tfn13-vhrm-5-315){ref-type="table-fn"}   1.344--2.893       1.312                                              0.852--2.021
  Total cholesterol (mg/dl)                                              1.002                                              0.997--1.006       1.000                                              0.994--1.005
  HDL-cholesterol (mg/dl)                                                0.993                                              0.982--1.003       1.008                                              0.994--1.022
  Triglyceride (mg/dl)                                                   1.004[b](#tfn13-vhrm-5-315){ref-type="table-fn"}   1.001--1.007       1.004[a](#tfn12-vhrm-5-315){ref-type="table-fn"}   1.000--1.008
  Antidyslipidemic medicine[c](#tfn16-vhrm-5-315){ref-type="table-fn"}   0.994                                              0.560--1.762       0.620                                              0.341--1.128
  FBG (mg/dl)                                                            1.004                                              0.986--1.022       0.981                                              0.961--1.001

**Abbreviations:** BMI, body mass index; SBP and DBP, systolic and diastolic blood pressure; HDL, high-density lipoprotein; FBG, fasting blood glucose.

**Notes:** ^a^P \< 0.05,

^b^P \< 0.01;

^c^Smoking,

^c^Antihypertensive medicine,

^c^Antidyslipidemic medicine (no = 1 and yes = 2).
